Table 1.
Clinical characteristics of 238 patients with hepatocellular carcinoma and 50 healthy controls
| Variable | HCC patients (n=238) | Healthy controls (n=50) |
|---|---|---|
| Age (years) | 59 (53–69) | 64 (53–71) |
| ≥65 | 93 (39.1) | 16 (32.0) |
| Male | 193 (81.1) | 40 (80.0) |
| Body mass index (kg/m2) | 23.7 (21.8–25.8) | 23.5 (21.7–25.4) |
| >25 | 80 (33.6) | 16 (32.0) |
| HBV/HCV/non-viral | 177/ 22/ 39 (69.7/ 9.2/ 21.1) | |
| Platelet (103/µL) | 131 (92–184) | 228 (161–296) |
| Albumin (g/dL) | 4.0 (3.5–4.3) | 4.5 (4.3–4.6) |
| Total bilirubin (mg/dL) | 0.8 (0.5–1.1) | 1.0 (0.8–1.3) |
| AST (U/L) | 44 (32–72) | 21 (19–29) |
| ALT (U/L) | 37 (23–55) | 21 (18–27) |
| Prothrombin time (INR) | 1.02 (1.0–1.14) | 1.01 (0.88–1.15) |
| Sodium (mmol/L) | 138 (136–140) | 142 (139–144) |
| Creatinine (mg/dL) | 0.8 (0.67–0.96) | 1.1 (1.0–1.2) |
| Child-Pugh class A/B | 204 (85.7)/34 (14.3) | |
| MELD score | 4 (2–6) | |
| Presence of cirrhosis | 171 (71.8) | |
| Alpha-fetoprotein (ng/mL) | 21.7 (4.0–837.4) | |
| Tumor size (cm) | 3.5 (2–7.3) | |
| TNM stage I/II/III/IV | 111 (46.6)/43 (18.1)/80 (33.6)/4 (1.7) | |
| BCLC stage 0/A/B/C | 43 (18.1)/95 (39.9)/43 (18.1)/57 (23.9) | |
| Initial therapy | ||
| Resection/RFA | 8 (3.4)/38 (16.0) | |
| TACE/systemic therapy | 187 (78.6)/3 (1.3) | |
| Follow-up (months) | 31.9±9.2 | |
| Number of deaths | 45 (18.9) | |
| Recurrence free survival (months) | 19.5 (0.7–66.4) | |
| Overall survival (months) | 31.9 (1.1–67.9) |
Values are presented as median (interquartile range), mean±standard deviation, or number (%).
HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio; MELD, model for end-stage liver disease; BCLC, Barcelona Clinic Liver Cancer; RFA, radiofrequency ablation; TACE, transarterial chemoembolization.